Positive results for Tagrisso-savolitinib combination

Preliminary results from the Savannah Phase II trial showed that the combination of Tagrisso (osimertinib) and savolitinib demonstrated an objective response rate of almost 50% in patients.

The study looked into the effectiveness of the drug combination in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with high levels of MET overexpression and/or amplification, whose disease progressed on treatment with Tagrisso. The safety profile of Tagrisso plus savolitinib was consistent with the known profiles of the combination and each treatment alone.

"Savolitinib added to Tagrisso at the time of disease progression could possibly provide these biomarker-selected patients with a potentially less toxic, more effective treatment"